OCT 2018

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link:

Contents of this Issue


Page 62 of 68

60 OCTOBER 2018 | MedEsthetics MERZ CREATES NEW AMERICAS DIVISION Bob Rhatigan, CEO of Merz North America, has been ap- pointed to a new position in the company: president and CEO of Merz-Americas. This expands Rhatigan's leadership of Merz's North American business as he assumes responsibility for Latin America and will oversee the overall commercial strategy for the company's newly created "Americas Region." In addition, Frank Brandt-Pollmann has been promoted to area vice president, Latin America. He will lead Merz's business operations across Latin America and report directly to Rhatigan. With the creation of the new Americas Region, Merz is focused on strengthening its business in North and Latin America (LATAM), which is home to some of the world's top aesthetics markets, including the U.S., Brazil and Mexico. "I am honored to accept this new leadership role within Merz, and I believe that our increased focus on the Americas creates an exciting strategic op- portunity to strengthen our partnerships with customers in these important markets," said Rhatigan. ALTAVILLA NAMED COO OF SUNEVA Suneva Medical has promoted industry veteran and vice president of sales and marketing, Patricia Altavilla to chief operating offi cer. Altavilla joined Suneva Medical in October 2016 and brings more than 30 years' experience in the aesthetics and medical fi elds to the position. Previously, she served as VP of international sales and world- wide marketing for Mentor Corporation, VP of sales, marketing and operations at The Plastic Surgery Company, and VP of global marketing at BioForm Medical. ORTHO DERMATOLOGICS ANNOUNCES ASPIRE HIGHER SCHOLARSHIP WINNERS Ortho Dermatologics, a division of Bausch Health Companies, has announced the 2018 honorees of its Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students who have been affected by dermatologic conditions. This year nine students will receive scholarships of $10,000 each to pursue graduate or undergraduate degrees at an accredited, nonprofi t, two- or four-year college, university, or advanced (post- high school) vocational or technical school. The recipients were selected from nearly 1,200 applicants, based in part on essays sharing their experiences living with a dermatologic condition, as well as the role that a dermatologist, physician assistant or nurse practitioner has played in helping treat it. The program recognizes students at varying stages of their educational careers through scholarships in three categories, including the Undergraduate Scholar Awards for those pursuing undergraduate degrees, the Graduate Scholar Awards for those pursuing graduate degrees and the Today's Woman Scholar Awards for mothers pursuing undergraduate or graduate degrees. The honorees include: Undergraduate Scholar Award • Jayla Chanel Davis, Alabaster, AL – University of South Alabama • Daisy Pena, San Jose, CA – California State University Long Beach • Mary Margaret Jordan, Melissa, TX – Baylor University Graduate Scholar Award • Zoe Smith, Ferndale, MI – Wayne State School of Medicine • Niki Vora, Buena Park, CA – UC Berkeley/UCSF Joint Medical Program • Caitlin Parker, Taylorsville, UT – Roseman University of Health Sciences, College of Dental Medicine Today's Woman Scholar Award • Laura Lukens, Evanston, IL – Northwestern University, Kellogg School of Management • Elizabeth Hendrix, Holladay, UT – University of Utah • Jennifer Hurley, Hammonton, NJ – Fairleigh Dickinson University The 2019 Aspire Higher scholarship program will begin accepting applications in early 2019. To learn more, visit BONTI RELEASES SCAR REDUCTION TRIAL DATA Biotechnology company Bonti has released topline results of its SHINE-1 (Scar Healing Improvement with Neurotoxin E) Phase 2a clinical trial, which evaluated the company's EB-001A for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profi le characterized by a faster onset of action (within 24 hours) and a shorter duration of activity (two to four weeks) compared to botulinum neurotoxin serotype A (BoNT/A) products. For the randomized, placebo-controlled, double-blind trial, EB-001A or placebo was administered to the frontalis muscle im- mediately after Mohs surgery for skin lesions in the forehead in 12 subjects (eight active, four placebo). Subjects were followed for up to 90 days post-treatment. Based on Visual Analog Scale (VAS) scores by the investiga- tor on Day 30, EB-001A-treated subjects' scars were about 50 percent better in appearance compared to scars in the placebo subjects. At 24 hours post-surgery, none of the EB-001A treated subjects reported itching, compared to 75 percent of placebo subjects who reported itching in the same time frame. Subjects treated with the active also reported less pain at 24 hours and NEWS & EVENTS Bob Rhatigan

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - OCT 2018